相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Relative safety of Gemfibrozil and Fenofibrate in the absence of concomitant Cerivastatin use
Noa Holoshitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Difficulty of mode of action determination for trichloroethylene: An example of complex interactions of metabolites and other chemical exposures
Jane C. Caldwell et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2008)
Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Pparα-null mice
Kayoko Takashima et al.
JOURNAL OF OCCUPATIONAL HEALTH (2008)
Mode of action frameworks: A critical analysis
Kathryn Z. Guyton et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2008)
Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths
Cynthia J. Wolf et al.
TOXICOLOGICAL SCIENCES (2008)
The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha
Qian Yang et al.
TOXICOLOGICAL SCIENCES (2008)
Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor α synthetic ligands in mouse liver
Dongsheng Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor α
Igor P. Pogribny et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2007)
Present concepts and outlook: Function of proliferator-activated receptors (PPARs) for future peroxisome pathogenesis, progression, and therapy of cancer
P. Sertznig et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Peroxisome proliferator-activated receptor α polymorphisms and postprandial lipemia in healthy men
Toshiko Tanaka et al.
JOURNAL OF LIPID RESEARCH (2007)
Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor α-independent pathway
Yuki Ito et al.
JOURNAL OF OCCUPATIONAL HEALTH (2007)
Induction of peroxisome proliferator-activated receptor alpha (PPARα)-related enzymes by di(2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not marmosets
Yuki Ito et al.
ARCHIVES OF TOXICOLOGY (2007)
Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis
Qian Yang et al.
CARCINOGENESIS (2007)
Genomic profiling in nuclear receptor-mediated toxicity
Courtney G. Woods et al.
TOXICOLOGIC PATHOLOGY (2007)
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis
Scott R. Freeman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Correction to the FIELD study report
Anthony Keech et al.
LANCET (2006)
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trial (VA-HIT)
E. Shyong Tai et al.
ATHEROSCLEROSIS (2006)
Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver
Ivan Rusyn et al.
CRITICAL REVIEWS IN TOXICOLOGY (2006)
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis
K Morimura et al.
CARCINOGENESIS (2006)
Gemfibrozil in the treatment of dyslipidemia -: An 18-year mortality follow-up of the Helsinki Heart Study
L Tenkanen et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Weight of evidence: A review of concept and methods
DL Weed
RISK ANALYSIS (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Peroxisome proliferator-activated receptor-α and liver cancer:: where do we stand?
JM Peters et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Lack of direct mitogenic activity of dichloroacetate and trichloroacetate in cultured rat hepatocytes
JL Walgren et al.
TOXICOLOGY (2005)
Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998
LS Gold et al.
TOXICOLOGICAL SCIENCES (2005)
Evidence-based toxicology: a comprehensive framework for causation
PS Guzelian et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2005)
Species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) in several organs of mice, rats, and marmosets
Y Ito et al.
ARCHIVES OF TOXICOLOGY (2005)
Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis
ML O'Brien et al.
CRITICAL REVIEWS IN TOXICOLOGY (2005)
Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of type 2 diabetes
DM Flavell et al.
DIABETES (2005)
Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono (2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets
W Kessler et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys
DJ Hoivik et al.
CARCINOGENESIS (2004)
Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor α (PPARα)
P Howroyd et al.
TOXICOLOGIC PATHOLOGY (2004)
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes
C Foucher et al.
PHARMACOGENETICS (2004)
Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α
C Cheung et al.
CANCER RESEARCH (2004)
Activation of PPARα and PPARγ by environmental phthalate monoesters
CH Hurst et al.
TOXICOLOGICAL SCIENCES (2003)
Recent advances in peroxisome proliferator-activated receptor science
BG Shearer et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Bezafibrate induces a mitochondrial derangement in human cell lines: A PPAR-independent mechanism for a peroxisome proliferator
R Scatena et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2003)
Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial
Y Jamshidi et al.
ATHEROSCLEROSIS (2002)
Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease
DM Flavell et al.
CIRCULATION (2002)
Human peroxisome proliferator-activated receptor α (PPARα) supports the induction of peroxisome proliferation in PPARα-deficient mouse liver
ST Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Phthalates rapidly increase production of reactive oxygen species in vivo: Role of Kupffer cells
I Rusyn et al.
MOLECULAR PHARMACOLOGY (2001)
Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes
W Parzefall et al.
CARCINOGENESIS (2001)
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease
TW Meade
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE (2001)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
Peroxisome proliferator-activated receptor α is restricted to hepatic parenchymal cells, not Kupffer cells:: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
JM Peters et al.
CARCINOGENESIS (2000)
分享论文
